Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. With a performance of 5.28%, the BUY prediction by melinda for Alkermes plc closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | 0.348% | 0.348% | 104.425% | 61.538% |
| iShares Core DAX® | 0,85 % | 1,37 % | 2,61 % | 52,29 % |
| iShares Nasdaq 100 | -0,99 % | -3,84 % | 25,55 % | 78,88 % |
| iShares Nikkei 225® | -1,78 % | -8,53 % | 42,81 % | 65,51 % |
| iShares S&P 500 | 0,06 % | 0,61 % | 21,57 % | 63,55 % |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.